{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:07:21Z","timestamp":1767964041487,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study used retrospective chart review and survey data to evaluate: (1) off\u2010label use of rituximab (MabThera<jats:sup>\u00ae<\/jats:sup>\/Rituxan<jats:sup>\u00ae<\/jats:sup>) in autoimmune conditions and (2) patients\u2019 receipt and knowledge of the Patient Alert Card (PAC), a risk minimization measure for progressive multifocal leukoencephalopathy (PML) and serious infections. Anonymized patient data were collected from infusion centers in Europe from December 2015 to July 2017. Adults receiving rituximab in the same centers were provided a self\u2010administered survey. Outcomes included patterns of off\u2010label rituximab use for nononcology indications, and evaluation of patients\u2019 receipt and knowledge of the PAC and its impact. Of 1012 patients in the retrospective chart review, 70.2% received rituximab for rheumatoid arthritis or granulomatosis with polyangiitis\/microscopic polyangiitis, and 29.8% received rituximab off label. Among 524 survey participants, 32.8% reported receiving the PAC, 59.3% reported not receiving the PAC and 7.9% did not know whether they received the PAC. A total of 72.4% of patients reported that they were unaware that some patients receiving rituximab experience PML. A higher proportion of PAC recipients identified PML as a potential risk of rituximab than nonrecipients (37.8% vs 19.9%); 58.3% of PAC recipients had poor awareness of PML. Most PAC recipients (90.0%) and nonrecipients (85.5%) correctly answered that they should seek medical attention for infection symptoms. In conclusion, approximately 30% of patients received off\u2010label rituximab. Most patients reported not receiving the PAC or having knowledge of PML but demonstrated understanding of the recommended action in the event of infection symptoms, regardless of PAC receipt.<\/jats:p>","DOI":"10.1002\/prp2.555","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T20:00:06Z","timestamp":1578081606000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab utilization for approved and off\u2010label nononcology indications and patients\u2019 experiences with the Patient Alert Card"],"prefix":"10.1002","volume":"8","author":[{"given":"Khaled","family":"Sarsour","sequence":"first","affiliation":[{"name":"Genentech, Inc South San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senam","family":"Beckley\u2010Kartey","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Melega","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adefowope","family":"Odueyungbo","sequence":"additional","affiliation":[{"name":"Roche Products Ltd Mississauga ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Kirchner","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Khalife","sequence":"additional","affiliation":[{"name":"IQVIA Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Bangs","sequence":"additional","affiliation":[{"name":"Joanne Bangs Ltd Letchworth Garden City Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051"},{"key":"e_1_2_11_3_1","unstructured":"MabThera.Summary of product characteristics. Germany. Roche Registration GmbH.2019."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202293"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000163"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3337"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0615-7"},{"key":"e_1_2_11_10_1","unstructured":"MabThera.Patient Alert Card.https:\/\/www.medicines.org.uk\/emc\/rmm\/1065\/DocumentWelwyn Garden City United Kingdom. Roche Registration Limited. 2014. Accessed June 4 2019."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0289-8"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S139248"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-6343(09)72973-3"},{"key":"e_1_2_11_15_1","unstructured":"European Commission.Study on off\u2010label use of medicinal products in the European Union.https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/documents\/2017_02_28_final_study_report_on_off-label_use_.pdf. Published February 2017. Accessed June 4 2019."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13318"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T09:07:30Z","timestamp":1694164050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/prp2.555"],"URL":"https:\/\/doi.org\/10.1002\/prp2.555","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"2019-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00555"}}